Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | L1CAM-specific CAR+EGFRt+ T cells |
Synonyms | |
Therapy Description |
L1CAM-specific CAR+EGFRt+ T cells are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting L1CAM (CD171) and truncated EGFR (EGFRt), which may increase cytotoxicity against L1CAM-expressing tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
L1CAM-specific CAR+EGFRt+ T cells | CD171-specific CAR-EGFRt-expressing T lymphocytes | L1CAM-specific CAR+EGFRt+ T cells are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting L1CAM (CD171) and truncated EGFR (EGFRt), which may increase cytotoxicity against L1CAM-expressing tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06094842 | Phase I | L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | Not yet recruiting | USA | 0 |